Multi-omics analysis reveals Jianpi formula-derived bioactive peptide-YG-22 potentially inhibited colorectal cancer via regulating epigenetic reprogram and signal pathway regulation
This study demonstrates that combining chemotherapy with TCM Jianpi formula enriches the molecular landscape and generates bioactive peptides with strong antitumor activity. Furthermore, this study also lays the foundation for further development of peptide-based therapies and highlights the value of combining traditional and modern therapeutic strategies for CRC management.
Authors
- Bo Han (ORCID: https://orcid.org/0000-0001-5286-372X)
- Yuanyuan Li (ORCID: https://orcid.org/0009-0002-4448-1240)
- Mingming Ding
- Li‐Sheng Chang
- Li‐Juan Zhu (ORCID: https://orcid.org/0000-0003-3478-1725)
- Jun Wang (ORCID: https://orcid.org/0000-0002-5890-0365)
- Jun Lü (ORCID: https://orcid.org/0000-0002-7343-9706)
- Wenli Chen (ORCID: https://orcid.org/0000-0003-1717-1263)
- Xiyu Wang (ORCID: https://orcid.org/0009-0002-7558-6504)
- Qin Shi (ORCID: https://orcid.org/0000-0002-8694-2685)
- Bo Xiong (ORCID: https://orcid.org/0000-0001-7815-3603)
- Hongyu Chen (ORCID: https://orcid.org/0000-0002-5325-9249)
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
- Shanghai Chest Hospital (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Tongren Hospital (CN)
Publication Details
- Journal
- Frontiers in Genetics
- Published
- 2025-03-05
- DOI
- https://doi.org/10.3389/fgene.2025.1560172
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00